Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study
- PMID: 2687645
- DOI: 10.1016/0378-5122(89)90210-7
Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study
Abstract
In many patients with involutional osteoporosis anabolic steroids may produce a rapid subjective improvement and a pronounced reduction in the frequency of complaints. Animal experiments have demonstrated that anabolic steroids can also have an objective effect on bone tissue. Twenty (20) post-menopausal osteoporotic patients were randomly assigned to 2 different treatment regimens; 10 patients were treated with 50 mg i.m. of nandrolone decanoate (ND) every 3 wk for 12 mth and 10 patients were treated with a placebo. Both groups also received an oral calcium supplement (1 g/day). Bone mineral content (BMC) was measured by dual photon absorptiometry before and after 1, 3, 6 and 12 mth of treatment. Plasma alkaline phosphatase (ALP) and urinary hydroxyproline excretion were measured at the same time. Intestinal calcium absorption was measured by the 47Ca oral test before and after treatment. A transiliac bone biopsy was performed before and after treatment in 4 patients in each group. After 1 yr there was a significant increase in lumbar spine BMC in the group receiving calcium plus ND. A progressive increase in plasma ALP was also observed in the group treated with ND but this was not significant, whereas radiocalcium absorption did increase significantly in this group. Histomorphometric study of bone samples demonstrated a significant increase in trabecular bone volume (TBV) and in active osteoid surface area in the patients treated with ND. Because plasma ALP tends to increase when a small decrease in bone resorption occurs (as measured by urinary hydroxyproline excretion) and the active osteoid surfaces also significant augment, we concluded that ND therapy increases the bone formation rate through inhibition of bone resorption. This interpretation could explain the considerable increase in lumbar spine BMC and the significant increase in TBV observed in patients treated with ND.
Similar articles
-
Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.Clin Rheumatol. 1995 Sep;14 Suppl 3:32-9. doi: 10.1007/BF02210686. Clin Rheumatol. 1995. PMID: 8846659 Review.
-
Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.Osteoporos Int. 1997;7(1):29-35. doi: 10.1007/BF01623456. Osteoporos Int. 1997. PMID: 9102059 Clinical Trial.
-
[Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].Minerva Endocrinol. 1989 Jan-Mar;14(1):69-74. Minerva Endocrinol. 1989. PMID: 2659955 Clinical Trial. Italian.
-
Effects of nandrolone decanoate on bone mass in established osteoporosis.Maturitas. 1993 Nov;17(3):211-9. doi: 10.1016/0378-5122(93)90049-n. Maturitas. 1993. PMID: 8133796 Clinical Trial.
-
Strontium ranelate in osteoporosis.Curr Pharm Des. 2002;8(21):1907-16. doi: 10.2174/1381612023393639. Curr Pharm Des. 2002. PMID: 12171530 Review.
Cited by
-
Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.Clin Rheumatol. 1995 Sep;14 Suppl 3:32-9. doi: 10.1007/BF02210686. Clin Rheumatol. 1995. PMID: 8846659 Review.
-
Bone loss in men.Calcif Tissue Int. 1996 Jan;58(1):1-3. doi: 10.1007/BF02509537. Calcif Tissue Int. 1996. PMID: 8825230 Review. No abstract available.
-
Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.Osteoporos Int. 1997;7(1):29-35. doi: 10.1007/BF01623456. Osteoporos Int. 1997. PMID: 9102059 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical